What is the price-to-earnings ratio of Verastem?
The price-earnings ratio of Verastem is currently 13.21.
Verastem P/S 2024
Verastem P/S
13.21
Ticker
VSTM
ISIN
US92337C1045
WKN
A1JTPU
As of Oct 6, 2024, Verastem's P/S ratio stood at 13.21, a 0% change from the 0 P/S ratio recorded in the previous year.
The Verastem P/S history
Verastem Aktienanalyse
What does Verastem do?
Verastem Inc. is a biopharmaceutical company founded by Dr. Christoph Westphal in Cambridge, Massachusetts, in 2010. The company focuses on developing drugs for the treatment of cancer and other serious diseases using technologies based on small molecules and RNA interference. The company specializes in developing therapies for patients with particularly aggressive types of cancer, such as diffuse large B-cell lymphoma (DLBCL), mesothelial tumors, liver cancer, and pancreatic cancer. Verastem collaborates closely with leading academic research institutions and clinics around the world to test and validate the efficacy and safety of its therapies. Verastem's business model is based on identifying and developing drug candidates based on the needs of patients with serious diseases. The company uses patented screening technologies to identify compounds that selectively target specific cancer cells without harming healthy cells. These compounds are then tested in preclinical and clinical studies to demonstrate their efficacy and safety for use in humans. One of Verastem's main areas of focus is the development of drugs that target signaling pathways in cancer cells. The company has several drugs in its pipeline that aim to inhibit proteins that are central to the growth and survival of cancer cells. These include VS-6063, VS-5584, and VS-5095. VS-6063 is a small molecule that targets the inhibition of the Focal Adhesion Kinase (FAK) protein. FAK plays a key role in the development and progression of cancer by promoting the growth and movement of cancer cells. VS-6063 is currently being studied in clinical trials for the treatment of mesothelioma, pancreatic cancer, and other types of cancer. VS-5584 is a small molecule that targets the inhibition of the mammalian Target of Rapamycin (mTOR) protein. mTOR is an important regulator of cell growth and division that is overactive in many types of cancer. VS-5584 is currently being studied in clinical trials for the treatment of liver cancer and other types of cancer. VS-5095 is a small molecule that targets the inhibition of the Wnt protein, which plays a crucial role in regulating cell proliferation and differentiation. Wnt is also involved in the development of cancer as it can contribute to the transformation of normal cells into cancer cells. VS-5095 is currently in preclinical studies for the treatment of various types of cancer. Verastem also has a promising pipeline of RNA interference therapies that aim to inhibit the expression of specific genes in cancer cells. One such therapy currently in clinical testing, VS-6061, targets the inhibition of the KRAS gene, which is mutated in many types of cancer and can promote the survival and growth of cancer cells. Overall, Verastem aims to develop drugs that are better tailored to the individual needs of patients and help them fight their disease. With its innovative research approach and strong pipeline of drug candidates, the company has the potential to fundamentally change the way cancer is treated. Verastem ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Verastem's P/S Ratio
Verastem's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Verastem's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Verastem's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Verastem’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Verastem stock
How has the price-earnings ratio of Verastem changed compared to last year?
The price-to-earnings ratio of Verastem has increased by 0% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Verastem high compared to other companies?
Yes, the price-to-earnings ratio of Verastem is high compared to other companies.
How does an increase in the price-earnings ratio of Verastem affect the company?
An increase in the price-earnings ratio of Verastem would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Verastem affect the company?
A decrease in the price-earnings ratio of Verastem would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Verastem?
Some factors that influence the price-earnings ratio of Verastem are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Verastem pay?
Over the past 12 months, Verastem paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Verastem is expected to pay a dividend of 0 USD.
What is the dividend yield of Verastem?
The current dividend yield of Verastem is .
When does Verastem pay dividends?
Verastem pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Verastem?
Verastem paid dividends every year for the past 0 years.
What is the dividend of Verastem?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Verastem located?
Verastem is assigned to the 'Health' sector.
Wann musste ich die Aktien von Verastem kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Verastem from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
When did Verastem pay the last dividend?
The last dividend was paid out on 10/6/2024.
What was the dividend of Verastem in the year 2023?
In the year 2023, Verastem distributed 0 USD as dividends.
In which currency does Verastem pay out the dividend?
The dividends of Verastem are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Verastem
Our stock analysis for Verastem Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Verastem Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
